Proprotein convertase subtilisin/kexin type 9 inhibitors: clinical efficacy and safety

PCSK9 inhibitors arrived promising LDL reductions beyond anything statins could reach. This review takes stock of what the big outcome trials actually delivered.

The evidence base is two landmark trials — FOURIER (evolocumab, ~27,500 patients) and ODYSSEY OUTCOMES (alirocumab, ~19,000) — and the authors summarize a consistent result: added to statins, these drugs cut LDL cholesterol by more than half and significantly reduced major cardiovascular events, without major safety surprises even at very low LDL levels. What the trials didn’t clearly show was a mortality benefit, and the cost is substantial.

The practical takeaway is targeted: for high-risk patients who remain above their LDL goal on maximally tolerated statins (with or without ezetimibe), adding a PCSK9 inhibitor meaningfully lowers risk. The resistance is economic — high price and the absent mortality signal give insurers and some clinicians reason to restrict access.

We rate the evidence moderate as presented: a brief (20-reference) narrative review, but resting on definitive randomized trials with hard endpoints and no major author conflicts. Its clinical significance is high — these drugs address a real gap for patients statins can’t get to goal — bounded mainly by cost and access rather than by doubt about whether they work.